Mehnert, J. M., Mehmi, I., Goldberg, J. D., Dimitrova, M., Arriola, P., Puranik, A., Mizutani, T., Idga, S., Li, X., Levinson, B. A., Cohen, J. V., Buchbinder, E. I., Lawrence, D. P., Kalyan, A., Simons, M., Levine, J. M., Hodi, F. S., Sullivan, R. J., Hamid, O. (2025). A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.9510